Economic Evaluation of the Addition of Vancomycin to Cefazolin Prophylaxis in Patients Undergoing Arthroplasty
Adding vancomycin to cephazolin prophylaxis in arthroplasty is most likely not cost-effective. Omitting vancomycin could lead to substantial annual savings for the healthcare sector without compromising health outcomes.
Authors
- Trisha Peel (ORCID: https://orcid.org/0000-0003-2370-2438)
- Ross Crawford (ORCID: https://orcid.org/0000-0001-6079-1316)
- Janine Roney
- Tim Spelman
- Kirsty Buising (ORCID: https://orcid.org/0000-0001-6090-4931)
- Tiffany Harris-Brown
- Michael Solomon
- Johnthan Mulford
- An Tran-Duy
- Sarah Asbury
- Sam Adie
- Catherine McDougall
- the ASAP Trial Group
- Richard de Steiger
- David L. Paterson
- Robert Molnar
Institutions
- The Royal Melbourne Hospital (AU)
- Burnet Institute (AU)
- Queensland University of Technology (AU)
- The University of Queensland (AU)
- The University of Melbourne (AU)
- National University of Singapore (SG)
- Sutherland Hospital (AU)
- Launceston General Hospital (AU)
- Epworth Hospital (AU)
- Peter MacCallum Cancer Centre (AU)
- St Vincent's Hospital Melbourne (AU)
- Peter Doherty Institute (AU)
- Prince of Wales Hospital (AU)
- Prince Charles Hospital (AU)
- National University Health System (SG)
- Melbourne Health (AU)
- Monash University (AU)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1007/s40273-026-01609-0
- Primary Topic
- Orthopedic Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medical Research Council
- National Health and Medical Research Council